MET
US EQUITY
Financials
Life & Health Insurance
CIK: 1099219
MetLife (MET) Quant Factor Diagnostic & Fair Value Model
MetLife (Ticker: MET) is listed in the Financials sector (Life & Health Insurance). Below is its point-in-time financial profile, valuation multiples, and cross-sectional factor diagnostics.
$98.82
-4.59%
Latest Close (2026-10-23)
Market Cap: $73.02B
P/E Ratio: 22.7
Momentum Strength
3M / 12M
+3.81%
1M: +1.61%
12M: +25.79%
Quality (ROE)
Point-in-Time
+10.53%
Trailing Return on Equity
Technical Trend
RSI 14
55.2
SMA50: $97.26
SMA200: $85.15
Valuation Multiplier
Trailing
22.7
Moderate Valuation Corridor (15x - 30x P/E)
📊
Valuation & Multi-Factor Diagnostic
Moderate Valuation Corridor (15x - 30x P/E)
MET trades within a typical sector multiple band (22.7x P/E), broadly aligned with trailing earnings.
⚡
Benchmark Factor Strategy
S&P 500 Momentum Alpha Strategy
This strategy applies cross-sectional momentum and quality factor filters across large-cap US equities.
📈 Daily Candlestick & Volume Quant Chart
Interactive lightweight price action & volume breakdown over recent 90 trading days.
均线多头 (MA20/50)
Piotroski F-Score: 8/9 (High Financial Strength)
Official Point-in-Time Financial Filing History
Zero Lookahead Bias: Every financial metric is timestamped at the exact moment officially published to the market.
备案 CIK: 1099219 · 10-K 年报 / 10-Q 季报
| Form | Period End | Filing Timestamp (Point-in-Time) | Revenue | Net Income | Operating CF | EPS (Diluted) |
|---|---|---|---|---|---|---|
| 10-Q | 2026-06-30 | 2026-08-06 | $19.15B | $736.00M | $4.92B | $1.09 |
| 10-Q | 2025-12-31 | 2026-08-06 | - | - | - | - |
| 10-Q | 2025-06-30 | 2026-08-06 | $17.34B | $729.00M | $6.45B | $1.03 |
| 10-Q | 2026-03-31 | 2026-05-07 | $19.07B | $1.19B | $2.69B | $1.74 |
| 10-Q | 2025-03-31 | 2026-05-07 | $18.57B | $945.00M | $4.26B | $1.28 |
| 10-K | 2025-12-31 | 2026-02-19 | $77.08B | $3.38B | $17.09B | $4.71 |
| 10-K | 2024-12-31 | 2026-02-19 | $70.99B | $4.43B | $14.60B | $5.94 |
| 10-K | 2023-12-31 | 2026-02-19 | $19.03B | $607.00M | $13.72B | $0.77 |
💡 Methodology & Frequently Asked Questions
Key reference details regarding MetLife (MET) valuation multiples, momentum factors, and point-in-time filing conventions.
How should MET's current valuation multiple be interpreted? ↓
MET trades at a trailing P/E of 22.7x within the Financials sector (moderate valuation corridor (15x - 30x p/e)). Valuation multiples are computed using trailing-twelve-month GAAP earnings against the latest close price.
What are MET's key momentum and technical factor indicators? ↓
As of the latest close, MET shows a 1-month return of +1.61%, 3-month return of +3.81%, and 12-month return of +25.79%, with a 14-day RSI of 55.2. Momentum factors reflect short- and intermediate-term price velocity across the equity cross-section.
What is Point-in-Time (PIT) financial data and why does it matter for MET? ↓
Point-in-Time indexing aligns corporate fundamentals with their official public filing timestamps (Form 10-Q/10-K) rather than accounting period-end dates. This methodology eliminates lookahead bias in historical equity backtests.
How can MET be incorporated into systematic factor models? ↓
MET can be evaluated within customized multi-factor models or screened against cross-sectional filters (such as momentum quintiles and return on equity) to analyze historical turnover and risk-adjusted return.